6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 10 of 2,298 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04147949 (ClinicalTrials.gov)	August 2022	27/10/2019	AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia	Randomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Effi ...	Parkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic Use	Drug: AV-101;Drug: Placebo	VistaGen Therapeutics, Inc.	NULL	Not yet recruiting	30 Years	80 Years	All	20	Phase 2	NULL
2	NCT04373317 (ClinicalTrials.gov)	May 1, 2022	29/4/2020	Pimavanserin vs. Quetiapine for the Treatment Parkinson's Psychosis	CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin an ...	Parkinson's Disease Psychosis	Drug: Pimavanserin;Drug: Quetiapine	VA Office of Research and Development	NULL	Not yet recruiting	40 Years	N/A	All	358	Phase 4	United States
3	NCT05094011 (ClinicalTrials.gov)	May 1, 2022	20/7/2021	Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects Wit ...	A Phase I Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Aut ...	Idiopathic Parkinson's Disease	Biological: Aadipose-Derived Mesenchymal Stem Cells	Taiwan Mitochondrion Applied Technology Co., Ltd.	NULL	Not yet recruiting	45 Years	70 Years	All	9	Phase 1	NULL
4	NCT05197439 (ClinicalTrials.gov)	April 1, 2022	5/1/2022	Dexmedetomidine Prevents Postoperative Delirium After Deep Brain Stimulation in Patients With Parkin ...	Effect of Dexmedetomidine on Postoperative Delirium in Elderly Patients With Parkinson's DiseaseUnde ...	Dexmedetomidine;Postoperative Delirium;Deep Brain Stimulation	Drug: Dexmedetomidine;Drug: 0.9% saline	Beijing Tiantan Hospital	NULL	Not yet recruiting	60 Years	N/A	All	182	N/A	China
5	NCT05258071 (ClinicalTrials.gov)	March 2022	10/2/2022	A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Di ...	A Randomised, Placebo-controlled, Multicentre Phase IIb Study Evaluating the Efficacy of Pirepemat o ...	Parkinson Disease	Drug: Pirepemat;Drug: Placebo	Integrative Research Laboratories AB	NULL	Not yet recruiting	55 Years	85 Years	All	165	Phase 2	NULL
6	EUCTR2021-000041-40-NL (EUCTR)	22/02/2022	10/11/2021	A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and ...	A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and ...	Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Psilocybin INN or Proposed INN: Psilocybine Product Name: Ketamine INN or Proposed INN: K ...	Maastricht University	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	34	Phase 2	Netherlands
7	NCT04957095 (ClinicalTrials.gov)	February 18, 2022	29/6/2021	Motor Network Physiology	Motor Network Physiology Characterization During Deep Brain Stimulation Surgery	Parkinson Disease;Essential Tremor	Drug: Inbrija;Other: Subcortical Stimulation	University of Texas Southwestern Medical Center	University of California, Los Angeles;National Institute of Neurological Disorders and Stroke (NINDS ...	Recruiting	18 Years	89 Years	All	120		United States
8	NCT05287503 (ClinicalTrials.gov)	February 15, 2022	28/1/2022	Ambroxol as a Disease-modifying Treatment in GBA-PD	Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associat ...	Parkinson Disease;GBA Gene Mutation	Drug: Ambroxol Hydrochloride;Drug: Placebo	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	University of Campania Luigi Vanvitelli;IRCCS National Neurological Institute C. Mondino Foundation	Recruiting	21 Years	80 Years	All	60	Phase 2	Italy
9	NCT05266417 (ClinicalTrials.gov)	February 7, 2022	23/2/2022	Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, ...	Parkinson Disease	Drug: INS-GSH;Drug: Matched Placebos	Gateway Institute for Brain Research	NULL	Recruiting	30 Years	85 Years	All	56	Phase 2	United States
10	NCT05205291 (ClinicalTrials.gov)	February 1, 2022	9/11/2021	Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR	Molecular Imaging of LPS-induced Microglial Activation in Parkinson's Disease(PD). A TSPO PET-MR Ima ...	Neurodegenerative Diseases;Parkinson Disease	Drug: Lipopolysaccharide;Radiation: PET/MR with [11C]PBR28	University of Exeter	NULL	Recruiting	50 Years	85 Years	All	24		United Kingdom

First Previous1 2 3 4 5…230Next Last